Navigation Links
Novavax Reports First Quarter 2009 Financial Results
Date:5/8/2009

p>

  • Top line results from the phase II trial in healthy adults with our trivalent seasonal flu vaccine candidate;
  • Preclinical results of studies with vaccine candidates against the Respiratory Syncitial Virus (RSV);
  • Commencement of operations of the joint venture with Cadila Pharmaceuticals Ltd in India; and,
  • Initiation of a Phase II clinical study of our trivalent seasonal flu vaccine in older adults.

2009 Financial Results

Revenue from operations for the first quarter ended March 31, 2009 was $0.02 million compared to $0.5 million for the same period in 2008, a net decrease of $0.4 million due to the completion of a government contract in the first quarter of 2009.

Research and development costs for the first quarter of 2009 were $4.3 million compared to $4.4 million in the first quarter of 2008. The decrease was due to a $0.2 million decrease in employee costs and a $0.1 million decrease associated with the closing of the Taft Court facility in October 2008 when the Company consolidated its operations into the Belward Campus facility. These decreases were partially offset by an increase in $0.1 million in outside testing costs associated with the continuing clinical trials, preclinical testing, process development, manufacturing and quality related programs and a $0.1 million increase in facility costs.

General and administrative costs were $2.9 million in the first quarter of 2009 as compared to $3.2 million in the first quarter of 2008. The $0.3 million decrease was due to a decrease in employee costs of $0.1 million, a decrease in facility costs associated with general and administrative functions of $0.1 million, and a decrease of $0.2 million in charges to the allowance established for two notes receivable from former directors. The Company determined that the notes receivable
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
2. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
3. Novavax Announces Early Retirement of $17 Million of Convertible Debt
4. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
5. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
6. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
7. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
8. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
9. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
10. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
11. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014 -- A novel combination of microscopy and ... Energy,s Oak Ridge National Laboratory an unprecedented look at ... physical and electrochemical properties. , The research team ... the surface of a perovskite manganite, a complex material ... avenue to understand surface behavior could benefit researchers who ...
(Date:7/24/2014)... 2014  Now available is a stem cell therapy ... Therapies , located in Guadalajara, Mexico ... a new health option: stem cell therapies for ... patients suffer from joint and muscle injuries due to ... torn rotator cuff, tennis elbow, and knee injuries. Throughout ...
(Date:7/24/2014)...  ECC West Africa, LLC (ECC) signed a contract ... College Hospital (UCH) Ibadan Board of Management for the ... construct, and operate and maintain a new, state-of-the-art Cancer ... the first of the 4-phase project, ECC will conduct ... UCH Ibadan intends to finance and develop the Cancer ...
(Date:7/24/2014)... leader Yung-Eun Sung has announced that they have ... graphenes which can be applied as high performance ... Sung is both a group leader at the ... Science* (IBS) and a professor at the Seoul ... with regards to the development of relative simplicity, ...
Breaking Biology Technology:ORNL study reveals new characteristics of complex oxide surfaces 2Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2
... and for opening new food and beverage product categories ... 16 Frost & Sullivan, the international growth consulting ... 2008 North American Food and Beverage Probiotics Product Innovation ... strain, Ganeden BC30 (TM), for opening new development ...
... - The American Journal of Medicine , ... Medicine (AJM), one of Elsevier,s flagship health,sciences journals, has introduced ... forum where physicians and other,healthcare professionals can discuss the research ... Journal. , "The American ...
... Reduced Use of Chemicals Among Greatest Benefits , ... ... a few developing countries that have made significant progress in plant ... released, Dr. Elíbio Rech, a biotechnology researcher at Embrapa in Brazil, ...
Cached Biology Technology:Ganeden Biotech Receives Frost & Sullivan 'Probiotics Product Innovation' Award 2Ganeden Biotech Receives Frost & Sullivan 'Probiotics Product Innovation' Award 3Elsevier Introduces The American Journal of Medicine Blog 2Elsevier Introduces The American Journal of Medicine Blog 3New Online Video Features Brazilian Researcher Elbio Rech 2New Online Video Features Brazilian Researcher Elbio Rech 3
(Date:7/27/2014)... Microorganisms like bacteria and fungi can evade treatment by ... antifungal drugs. These permanent mutations were once thought to ... Now a new study has shown that microorganisms can ... as epimutations -- to gain the benefits of drug ... was discovered in a fungus called Mucor circinelloides, it ...
(Date:7/25/2014)... 25, 2014 In the first broad-scale estimate of air ... and collaborators calculated that trees are saving more than ... of acute respiratory symptoms. , While trees, pollution removal ... than 1 percent, the impacts of that improvement are ... reduced air pollution at nearly $7 billion every year ...
(Date:7/25/2014)... Boston, MA A study published online in the ... describes a novel approach to preventing cervical cancer based ... cervical cancer after removal of a discrete population of ... from a study that looked at squamocolumnar junction cells, ... canal and have been implicated as the origins of ...
Breaking Biology News(10 mins):Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3First national study finds trees saving lives, reducing respiratory problems 2Clearing cells to prevent cervical cancer 2
... at the UAB,s Institute of Environmental Science and Technology ... analysed the potential of different species of microalgae for ... the quantity of lipids per cell (essential for obtaining ... of marine algae that has received little attention till ...
... Human Frontier Science Program Organization (HFSPO) is awarding $34 ... competition for the HFSP Research Grants. Applicants went through ... that started with 715 submitted letters of intent. This ... scientists) together with 23 Program Grants (involving 81 scientists). ...
... associate a picture with a reward, the reward by ... monkeys, visual cortex. This finding was made by neurophysiologists ... Medical School) and American colleagues using functional brain scans ... Neuron . Our visual perception is not determined ...
Cached Biology News:Microalgae could be a profitable source of biodiesel 2Impressive list of research teams for the 2013 HFSP Research Grants 2Reward linked to image is enough to activate brain's visual cortex 2
Evi-1 Antibody Shipping Temperature: Cold Storage Temperature: -20C...
... contains the basic components required for the ... and recombinant mouse Dickkopf homolog-1 (Dkk-1) in ... contains sufficient materials to run ELISAs on ... following conditions are met: The assay ...
The pCDF Expression System 1 plus Competent Cells contains 10 µg of pET-45b(+) DNA. pET-45b carries an N-terminal His•Tag ® coding sequence that is cleavable with enterokinase as well...
... Phosphorylase 1 ( Abpromise for all ... Synthetic peptide: MAATGANAEK AESHNDCPVR LLNPNIAKMK EDILYHFNLT TSRHNFPALF ... amino acids 1-99 of Human Uridine Phosphorylase ... 7378 Swiss Protein ...
Biology Products: